



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the June 2011 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS


Distribution of Respondent Types (n = 1569)



Q1. What percentage of the patients in your practice is being treated for metastatic breast cancer? (n = 1569)




Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?



Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?


By Geography†



†Note: Percentages may not total 100 because of rounding

Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?


By Geography † (continued)



†Note: Percentages may not total 100 because of rounding

Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?


By Practice Size †



†Note: Percentages may not total 100 because of rounding

Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?


By Practice Setting†



†Note: Percentages may not total 100 because of rounding


Q2. When selecting a 3rd line cytotoxic chemotherapy agent for the treatment of metastatic breast cancer, what is your level of importance for the following variables?

By Specialty†



†Note: Percentages may not total 100 because of rounding


Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?†



†Note: Percentages may not total 100 because of rounding

Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?


By Geography†



†Note: Percentages may not total 100 because of rounding

Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?


By Geography† (continued)



†Note: Percentages may not total 100 because of rounding

Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?


By Practice Size†



†Note: Percentages may not total 100 because of rounding

Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?


By Practice Setting†



†Note: Percentages may not total 100 because of rounding


Q3. For the following variables, what is the level of importance from your patients' perspective when they are being treated with 3rd line cytotoxic chemotherapy for metastatic breast cancer?

By Specialty†



†Note: Percentages may not total 100 because of rounding


Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?†



†Note: Percentages may not total 100 because of rounding

Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?

By Geography†




†Note: Percentages may not total 100 because of rounding

Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?

By Geography† (continued)


- Familiar and very likely to prescribe
- Familiar and somewhat likely to prescribe
- Familiar but not likely to prescribe
- Unfamiliar and therefore unlikely to prescribe



†Note: Percentages may not total 100 because of rounding

Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?


By Practice Size †



†Note: Percentages may not total 100 because of rounding

Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?


By Practice Setting†



†Note: Percentages may not total 100 because of rounding

Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?


By Specialty†



†Note: Percentages may not total 100 because of rounding


Q4. What is your familiarity with the following single agents and how likely are you to prescribe them for 3rd line cytotoxic chemotherapy in patients with metastatic breast cancer?

By Specialty† (continued)



†Note: Percentages may not total 100 because of rounding


Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?


By Geography†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?


By Practice Size †



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?


By Practice Setting†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?


By Specialty†



†Note: Percentages may not total 100 because of rounding

Q5. What is your level of interest in participating in the following to learn more about newly FDA-approved drugs?

By Specialty†



†Note: Percentages may not total 100 because of rounding

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.